Title :

Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.

Author(s) :

Sarkozy, Clémentine [Auteur]
Institut Curie [Paris]
Callanan, Mary Bridgid [Auteur]
Burgundy School of Business (BSB) - Ecole Supérieure de Commerce de Dijon Bourgogne (ESC) [BSB]
Thieblemont, Catherine [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Obéric, Lucie [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Burroni, Barbara [Auteur]
Hôpital Cochin [AP-HP]
Bouabdallah, Krimo [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Damaj, Ghandi [Auteur]
Université de Caen Normandie [UNICAEN]
Tessoulin, Benoit [Auteur]
Université de Nantes [UN]
Ribrag, Vincent [Auteur]
Institut Gustave Roussy [IGR]
Huout, Roch [Auteur]
Université de Rennes [UR]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Griolet, Samuel [Auteur]
The Lymphoma Academic Research Organisation [Lyon] [LYSARC]
Joubert, Clémentine [Auteur]
The Lymphoma Academic Research Organisation [Lyon] [LYSARC]
Cacheux, Victoria [Auteur]
CHU Clermont-Ferrand
Delwail, Vincent [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Safar, Violaine [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Gressin, Remy [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Cheminant, Morgane [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Delfau-Larue, Marie-Helene [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Hermine, Olivier [Auteur]
Imagine - Institut des maladies génétiques (IHU) [Imagine - U1163]
Macintyre, Elizabeth A. [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Le Gouill, Steven [Auteur]
Institut Curie [Paris]
Le Gouill, Steven [Auteur]

Journal title :

Blood

Abbreviated title :

Blood

Publication date :

2024-04-26

ISSN :

1528-0020

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Obinutuzumab (O) and Rituximab (R) are two CD antibodies that have never been compared in a prospective randomised trial in mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LYMA-101 (NCT02896582) ...
Show more >Obinutuzumab (O) and Rituximab (R) are two CD antibodies that have never been compared in a prospective randomised trial in mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LYMA-101 (NCT02896582) trial, in which newly diagnosed MCL patients were treated with chemotherapy plus O before transplantation followed by O maintenance (O group). We then compared these patients to those treated with the same treatment design with Rituximab instead of O (R group) (NCT00921414). A propensity score matching (PSM) was used to compare the two populations (O vs R groups) in terms of MRD at the end of induction (EOI), PFS and OS. In LYMA-101, the estimated five-year PFS and OS since inclusion (n=85) were 83.4% (95%CI: 73.5-89.8%) and 86.9% (95%CI: 77.6-92.5%), respectively. At EOI, patients treated in the O group had more frequent bone marrow MRD negativity than those treated in the R group (83.1% vs 63.4% Chi2 p=0.007). The PSM resulted in 2 sets of 82 patients with comparable characteristics at inclusion. From treatment initiation, the O group had a longer estimated five-year PFS (p=0.029; 82.8% versus 66.6%, HR 1.99, IC95 1.05-3.76) and OS (p=0.039; 86.4% versus 71.4% (HR 2.08, IC95 1.01-4.16) compared to the R group. Causes of death were comparable in the 2 groups, the most common cause being lymphoma. Obinutuzumab prior to transplantation and in maintenance provides better disease control and enhances PFS and OS, as compared to Rituximab in transplant-eligible MCL patients.Show less >

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Submission date :

2024-05-15T21:04:08Z
2024-06-06T13:12:08Z